Icosavax Inc ICVX shares are trading higher by 45.63% to $12.99 Thursday morning on continued strength after the company provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against respiratory syncytial virus.
The six-month immunogenicity update from the company's Phase 1/1b trial of IVX-121 against Respiratory Syncytial Virus (RSV) demonstrated a sustained neutralizing antibody (nAb) response against RSV, lasting at least six months after a single administration of IVX-121.
IVX-121 continued to be generally well-tolerated, with no safety concerns observed in this six-month follow-up and no vaccine-related serious adverse events (SAEs)...Read More
According to data from Benzinga Pro, Icosavax has a 52-week high of $25.63 and a 52-week low of $2.28.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
